NNC0537 1482
Alternative Names: NNC0537-1482Latest Information Update: 04 Dec 2024
Price :
$50 *
At a glance
- Originator Novo A/S
- Class Heart failure therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Heart failure
Most Recent Events
- 03 Oct 2024 Phase-I clinical trials in Heart failure (In volunteers) in Netherlands (SC), (NCT06625307),
- 03 Oct 2024 Preclinical trials in Heart failure (In volunteers) in Denmark (SC) before October 2024
- 03 Oct 2024 Novo Nordisk A/S plans a phase I trial in Heart Failure (In volunteers) in Netherlands (SC) in October 2024 (NCT06625307)